Previous 10 | Next 10 |
February 5, 2020 Palm Beach, FL –February 5, 2020 – Acute Myeloid Leukemia (AML) research has seen great progress with more researchers are now studying the causes, diagnosis, and treatment of Acute myeloid leukemia (AML) at many medical centers, university hospitals, an...
HOUSTON , Feb. 5, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it intends to discuss with the FDA and EMA (E...
VANCOUVER, British Columbia, Feb. 05, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “ Company ” or “ WPD ”), a clinical stage pharmaceutical company, is pleased to provide an update on its Annamycin Drug. Through its development p...
HOUSTON , Feb. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that its open label, single arm US Phase 1 tr...
VANCOUVER, British Columbia, Jan. 31, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company ” or “ WPD ”), a clinical stage pharmaceutical company, provides this update on the completed acquisition of exclusive sublicenses for tw...
HOUSTON , Dec. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the presentation of a poster entitled, ...
Schmitt Industries (NASDAQ: SMIT ) +13% on $2M stock repurchase plan . More news on: Schmitt Industries, Inc., EyePoint Pharmaceuticals, Inc., Kodiak Sciences Inc., Stocks on the move, Read more ...
December 4, 2019 Palm Beach, FL –December 4, 2019 – So it is not surprising that there is a lot of money and research resources being devoted to find new therapies for Acute Myeloid Leukemia (AML), many of which are in the targeted drugs arena. AML is the second most com...
HOUSTON , Dec. 4, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and effica...
SAExploration Holdings (NASDAQ: SAEX ) +183% on $130M of new projects in Alaska, Canada and the Middle East. More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., The Medicines Company, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...